The gap between sick-care and prevention
A standard Australian GP-ordered blood panel is designed to detect existing disease, not predict future risk. A typical panel covers a full blood count, basic lipids (total cholesterol, HDL, LDL, triglycerides), fasting glucose, liver enzymes (ALT, AST), kidney function (eGFR, creatinine), and TSH. These are useful for ruling out acute problems. They are poorly calibrated for identifying people who are metabolically drifting toward cardiovascular disease, diabetes, or cognitive decline a decade before symptoms appear.
A handful of additional markers can change that picture meaningfully — most are available in Australia, many are Medicare-eligible with clinical justification, and none require a specialist. The key is knowing what to ask for and why.
Markers worth adding to your panel
ApoB — a better measure of cardiovascular risk
Most panels measure LDL-cholesterol (LDL-C), which estimates the amount of cholesterol carried in LDL particles. ApoB measures something more fundamental: the actual number of atherogenic particles in the bloodstream, regardless of how much cholesterol each one carries. Because atherosclerosis is driven by particle number rather than cholesterol content, ApoB is a more direct predictor of cardiovascular events. Critically, LDL-C and ApoB are discordant in roughly 30% of people — meaning LDL-C alone can miss high-risk individuals and falsely reassure others. The 2019 European Society of Cardiology and European Atherosclerosis Society guidelines now recommend ApoB as the primary lipid target. Optimal: below 90 mg/dL for the general population, below 65 mg/dL for higher-risk individuals. Available in Australia; Medicare coverage with clinical indication.
HbA1c and fasting insulin — catching metabolic dysfunction early
A single fasting glucose reading can be normal even when significant insulin resistance is already present. HbA1c captures average blood glucose over 2–3 months, providing far more longitudinal signal. But the most sensitive early marker is fasting insulin. Hyperinsulinaemia — elevated insulin with normal glucose — is an independent cardiovascular risk factor that can precede glucose abnormalities by years. Most standard panels do not include fasting insulin despite it being the earliest indicator of metabolic trouble. Optimal HbA1c: below 5.5% for longevity-focused individuals (versus the standard normal cut-off of below 6.0%). Optimal fasting insulin: below 8 mIU/L. Must be specifically requested; HbA1c is Medicare-covered for diabetes screening.
hs-CRP — chronic inflammation at low levels
High-sensitivity C-reactive protein (hs-CRP) is a marker of systemic inflammation that independently predicts cardiovascular events beyond what cholesterol measurements capture. The landmark JUPITER trial (Ridker et al., 2008, NEJM, n=17,802) showed that statin therapy in people with normal LDL-C but elevated hs-CRP significantly reduced cardiovascular events — evidence that inflammation is a distinct risk pathway. Optimal: below 1.0 mg/L. Standard clinical "normal" is below 3.0 mg/L, which is too permissive from a longevity standpoint. Medicare-covered.
Lp(a) — the cardiovascular risk factor most people have never heard of
Lipoprotein(a), or Lp(a), is a genetically determined variant of LDL and an independent cardiovascular risk factor. It is elevated in roughly 20% of the population and associated with significantly higher risk of heart attack, stroke, and aortic stenosis. Lp(a) levels are 80–90% genetically determined, so they only need to be tested once. There is no currently approved treatment to meaningfully lower Lp(a), but knowing your level changes how aggressively other risk factors should be managed. The European Atherosclerosis Society consensus recommends universal testing at least once in adulthood. Ask your GP to include it — Medicare coverage may apply with justification.
The single test most Australians should add to their panel: Lp(a). It is genetically determined, only needs testing once, and independently predicts cardiovascular risk in 1 in 5 people. Most GPs never order it unless asked.
Vitamin D (25-OH) — common deficiency, specific populations
Despite Australia's reputation for sunshine, vitamin D deficiency is common — particularly in southern states, indoor workers, people with darker skin, and those over 65. Standard clinical normal is above 50 nmol/L; longevity-focused optimal is 100–150 nmol/L. However, the 2024 Endocrine Society guidelines are now more targeted: routine supplementation is primarily supported for adults over 75, people with prediabetes, pregnant women, and children. For healthy adults under 50 with reasonable sun exposure, supplementation is not routinely warranted — but knowing your level is still worthwhile. Medicare-covered annually.
Full thyroid panel — beyond TSH
Standard panels test only TSH (thyroid stimulating hormone). A raised TSH can flag hypothyroidism, but subclinical thyroid dysfunction — affecting 4–10% of adults — often requires free T3, free T4, and thyroid antibodies (anti-TPO, anti-thyroglobulin) to identify properly. Subclinical hypothyroidism is associated with cardiovascular risk and cognitive symptoms that may be reversible with treatment. If you have unexplained fatigue, weight changes, or a family history of thyroid disease, request the full panel. Partial Medicare coverage.
Iron studies and homocysteine
Standard panels often include serum iron but miss the more informative markers. Ferritin is both an iron storage indicator and an acute-phase reactant — elevated ferritin (above 300 ng/mL in men, above 200 in women) is associated with metabolic and cardiovascular risk independent of iron stores. Low ferritin (below 30 ng/mL) is associated with fatigue and cognitive impairment even in the absence of anaemia. Optimal range: 40–150 ng/mL. Homocysteine is a separate marker and an independent risk factor for cardiovascular disease and cognitive decline; it is B-vitamin dependent and treatable with B6, B12, and folate. Optimal: below 10 µmol/L. Both must be specifically requested.
How to access these in Australia
Most GPs will order additional markers with a brief clinical justification — framing the conversation as "I'd like to understand my cardiovascular and metabolic risk more completely" is usually sufficient. ApoB, HbA1c, hs-CRP, vitamin D, iron studies, and the full thyroid panel are all potentially Medicare-covered with appropriate indication. Lp(a) and fasting insulin may require some negotiation or a small out-of-pocket cost. Pathology providers including Sonic Healthcare, Australian Clinical Labs, and Healius process these through NATA-accredited labs. For most markers, annual testing is appropriate; Lp(a) only needs testing once.
The bottom line
Standard blood panels are calibrated for sick-care, not prevention. Adding ApoB, fasting insulin, hs-CRP, and Lp(a) to your baseline — plus HbA1c if you do not have it — can fundamentally change your understanding of your long-term risk profile. Most are available, most are affordable, and all are more actionable than the standard panel alone. The most important step is simply knowing what to ask for.
References
- Sniderman, A. D., et al. (2019). ApoB versus LDL-C for cardiovascular risk. Lancet Diabetes & Endocrinology.
- European Society of Cardiology / European Atherosclerosis Society (2019). ESC/EAS Guidelines for the management of dyslipidaemias.
- Ridker, P. M., et al. (2008). Rosuvastatin to prevent vascular events in patients with elevated CRP: JUPITER trial (n=17,802). New England Journal of Medicine.
- Tsimikas, S. & Hall, J. L. (2024). Lipoprotein(a) as a cause of cardiovascular disease. JACC.
- European Atherosclerosis Society Consensus Panel (2022). Lipoprotein(a): a genetically determined cardiovascular risk factor with causal evidence.
- Endocrine Society (2024). Clinical Practice Guideline: Vitamin D for the prevention of disease.
- Cappola, A. R. & Ladenson, P. W. (2003). Hypothyroidism and atherosclerosis. JAMA, 289(21).
- Medicare Benefits Schedule (2026). Relevant item numbers for pathology: lipids, glucose, inflammatory markers, thyroid, iron studies.
- Royal Australian College of General Practitioners (2024). Guidelines for preventive activities in general practice.